CRISPR Therapeutics CRSP Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's enterprise value?
- CRISPR Therapeutics (CRSP) reported enterprise value of $4.93B in Q1 2026.
- How has CRISPR Therapeutics's enterprise value changed year-over-year?
- CRISPR Therapeutics's enterprise value increased by 69.8% year-over-year, from $2.9B to $4.93B.
- What is the long-term trend for CRISPR Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's enterprise value has grown at a -14.5% compound annual growth rate (CAGR), from $10.61B to $4.86B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.